Sero-prevalence of HBsAg in naive HIV-infected patients in a rural locality of Cameroon

Molu, Jean-Patrick; Essome, Marie Chantal Ngonde; Monamele, Chavely Gwladys; Njouom, Richard

doi:10.1186/s13104-018-3159-2

Cited by 7 publications

(5 citation statements)

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The co-infection was 2.5% in their study population [10]. Our prevalence is low compared to Zoufaly et al and Molu et al who reported the prevalences of 12.6% in 2012% and 8.99% in 2018 respectively [6,11]. One of the most likely causes of the high prevalence of HBV-HIV co-infection is that both viruses have similar transmission pathways [12].…”

Section: Discussioncontrasting

confidence: 46%

See 1 more Smart Citation

HBV Seroprevalence and Genetic Diversity among HIV Patients in the Department of Lekoumou in Congo Brazzaville

Florient¹,

Clausina²,

Mboumba³

et al. 2018

Gastroint Hepatol Dig Dis

View full text Add to dashboard Cite

Introduction: HBV-HIV co-infection is a major public health problem. The objective of this study was to contribute to the improvement of management of HBV-HIV co-infected patients in Congo. Methods: This was a cross-sectional descriptive study conducted from January 1st to September 30th, 2016. We studied outpatients seen in hospitals and Integrated Health Center of Department of Lékoumou. Screening for HBsAg was done by rapid test (Heath Mate HBsAg plus test) and that of HIV 1 and 2 was done by immunoassay (ImmunocoCOMB II HIV). The detection of HBV DNA was made by the QIAGEN QIA Kit and the identification of genotypes by PCR product sequencing at the National Public Health Laboratory of Brazzaville. Results: During nine months of study period, 204 patients were enrolled to participate in this study. Male patients were 37.3% and female were 62.7%, with a sex ratio of 0.5. The mean age was 40.9 ± 13.4. The frequency of HBV-HIV co-infection was 2.4% (n = 5). Single infections accounted for 6.3% (n = 13) for HBV and 12.3% (n = 23) for HIV. Carriers of HBV DNA accounted for 7.8% (n = 16/204). Condom non-use was significantly associated with co-infection and mono-infection (P <0.05). HBV genotype E was more common in the study participants than genotype A. Conclusion: HIV-HBV co-infection exists. Despite the small sample size, the prevalence of infection with hepatitis B virus remains high. Two HBV genotypes, A and E, have been identified in co-infected and monoinfected patients.

show abstract

Section: Discussioncontrasting

confidence: 46%

“…Its seroprevalence in Congo was 3.2% between 2009 and 2013 [5]. Molu et al in 2018 reported an 8.9% prevalence of HBV infection in HIV-infected people in Cameroon [6]. In Congo, the exact prevalence of hepatitis B in the HIV population has not been accurately established.…”

Section: Introductionmentioning

confidence: 99%

HBV Seroprevalence and Genetic Diversity among HIV Patients in the Department of Lekoumou in Congo Brazzaville

Florient¹,

Clausina²,

Mboumba³

et al. 2018

Gastroint Hepatol Dig Dis

View full text Add to dashboard Cite

show abstract

“…In Cameroon, approximately 10% of HIV-infected patients are positive for HBsAg [9,[11][12][13]. National guidelines recommended HBsAg testing before starting ART in HIV-infected patients who show signs and symptoms of liver disease [14].…”

Section: Study Settingmentioning

confidence: 99%

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

et al. 2020

View full text Add to dashboard Cite

Background: Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon's national antiretroviral programme. Methods: A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models. Results: Of 1706 patients (women 74%, median age 42 years, median time on ART 3.9 years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p < 0.001). HBV testing was lower in women (adjusted odds ratio [aOR] 0.64, 95% confidence interval [CI] 0.46-0.89, p = 0.010) and higher in patients who initiated ART in 2010 or later (aOR 1.66, 95% CI 1.23-2.27, p < 0.001). Of 159 HBsAg-positive patients at the time of the study (9.3%), only 97 (61.0%) received Tenofovir + Lamivudine (or Emtricitabine). Of 157 coinfected patients, 114 (72.6%) had a HBV viral load < 10 IU/mL. HBV suppression was higher in patients with a HIV viral load < 300 copies/mL (aOR 3.46, 95% CI 1.48-8.09, p = 0.004) and lower in patients with increased ALT level (aOR 0.86 per 10 IU/mL increase, 95% CI 0.75-0.97, p = 0.019). Conclusions: A substantial proportion of HIV/HBV coinfected patients were at higher risk of liver disease progression. Improving the management of HBV infection in the routine healthcare setting in Africa is urgently required in order to achieve the 2030 elimination targets. Micro-elimination of HBV infection in people living with HIV could be an easier and cost-effective component than more widely scaling up HBV policies.

show abstract

“…Further, a retrospective control laboratory-based study showed an HBV rate of 16.2% among HIV patients from a more rural area of the country [14]. A study carried out on HIV patients in the Mfou community in Cameroon showed a Prevalence of HBsAg of 8.9% [15]. It is worth noting that this study did not present information about demographic risk factors, stage of HIV infection, and viral load.…”

Section: Introductionmentioning

confidence: 66%

Risk factors associated with response to highly active antiretroviral therapy after 24 months of administration to HIV, HIV/HBV and HCV patients in Kumba Health District, South West Region of Cameroon

Dickson¹,

Mbulli²,

Baptiste³

et al. 2022

Arch Clin Gastroenterol

View full text Add to dashboard Cite

Hepatitis B (HBV) and C (HCV) are two other forms of infections for which co-infection in HIV has been associated with alteration of the immune response, increased risk of progression to liver diseases, and increased risk of hepatotoxicity associated with antiretroviral therapy. This study aimed to establish the prevalence of hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb) among HIV patients, evaluate response to treatment between the different categories and identify the possible risk factors associated with this burden of hepatitis B/C among HIV patients and the resulting responses to HAART in Kumba Health, in the South West Region of Cameroon. Method: We performed a systematic screening using Rapid Diagnostic Test, for HBsAg and HCVAb among 299 HIV patients enrolled at the treatment centers in Kumba Health District (District hospital Kumba, Kumba Town Sub-Divisional hospital, and the Apostolic hospital Banga Bakundu), with all positives for HBV or HCV confirmed by the ELISA and results analyzed using SPSS version 20. Out of the 299 participants, 52 HIV patients, 36 HIV/HBV, and 12 HIV/HCV patients were involved in the prospective cohort study for 24 months which permitted monitored the immune response (CD4 counts and viral load test), as well as variation of biochemical parameters (ALAT/ASAT, albumin, bilirubine, creatinine) and weights of the studied participants. Result: Out of the 100 HIV patients involved in the prospective cohort, 36 and 12 were hepatitis B and C virus-positive respectively. Following the analysis of the viral load and CD4 cell counts, there were differences in response to HAART after 24 months between the mono-infected and co-infected patients, taking into consideration the, CD4 cell counts (HIV: 930.846 cells/mm3, HIV/HBV: 595.139 cells/mm3 and HIV/HCV: 678.500cells/mm3), and viral load (HIV: 1777.85copies/ml, HIV/HBV: 2232.61copies/ml and HIV/HCV: 750.83copies/ml). There were variations in biomarkers of the liver (ALAT/ASAT, bilirubin, and albumine) and renal function (creatinine) for both patients. There were also variations of the different biomarkers linked to the infection status of the different participants. Conclusion: There were positive variations in viral load and CD4 cell counts among the studied participants, with a more rapid response to the mono-infected HIV patients compared to the co-infected patients. Similar strength was observed in the variation of the different biomarkers and such variation indicates that co-infection of HIV patients with either hepatitis B or C virus can affect rapid response to HAART and the variations in the level of Biochemical markers among the different categories are linked to the alteration of the functions of the respective organs and so this result could be used for health decisions regarding co-infections.

show abstract

Sero-prevalence of HBsAg in naive HIV-infected patients in a rural locality of Cameroon

Cited by 7 publications

References 14 publications

HBV Seroprevalence and Genetic Diversity among HIV Patients in the Department of Lekoumou in Congo Brazzaville

HBV Seroprevalence and Genetic Diversity among HIV Patients in the Department of Lekoumou in Congo Brazzaville

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Risk factors associated with response to highly active antiretroviral therapy after 24 months of administration to HIV, HIV/HBV and HCV patients in Kumba Health District, South West Region of Cameroon

Contact Info

Product

Resources

About